Chen, Y-H <br/><br/>
Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes.  [electronic resource] 

 -  Eye (London, England)  Sep 2014 
 - 1080-6; quiz 1087 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1476-5454 
<br/><br/><label>Standard No.: </label>10.1038/eye.2014.172  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Axial Length, Eye--pathology<br/>Bevacizumab<br/>Child, Preschool<br/>Combined Modality Therapy<br/>Emmetropia--physiology<br/>Female<br/>Follow-Up Studies<br/>Gestational Age<br/>Humans<br/>Infant, Very Low Birth Weight<br/>Intravitreal Injections<br/>Laser Coagulation<br/>Male<br/>Myopia--epidemiology<br/>Prevalence<br/>Refraction, Ocular--physiology<br/>Retinopathy of Prematurity--drug therapy<br/>Retrospective Studies<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity--physiology<br/>Vitrectomy